Market revenue in 2023 | USD 20,384.4 million |
Market revenue in 2030 | USD 61,865.6 million |
Growth rate | 17.2% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.02% in 2023. Horizon Databook has segmented the Europe precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The burden of cancer continues to grow globally, exerting substantial pressure on patients, their families, communities, and healthcare systems. In Europe, cancer is the second-leading cause of death and morbidity, with over 3.7 million new cases and 1.9 million deaths each year. However, advancements in therapeutic approaches are bringing us closer to a future where cancer can be cured.
Over the past two decades, understanding of cancer has greatly improved, revealing significant variability not only between different cancer types but also among patients with the same type of cancer. This highlights the need for—and the promise of—tailoring cancer care to individual patient characteristics.
Fueled by this knowledge, cancer treatment is increasingly shifting toward PM, a healthcare approach that systematically uses patient data to inform personalized treatment decisions. The vision for precision medicine in cancer is transformative: to deliver superior outcomes for all cancer patients and ultimately reduce the suffering caused by cancer.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe precision medicine market , including forecasts for subscribers. This continent databook contains high-level insights into Europe precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account